[go: up one dir, main page]

UY33722A - Oxazolidinonas como moduladores de mglur5 - Google Patents

Oxazolidinonas como moduladores de mglur5

Info

Publication number
UY33722A
UY33722A UY0001033722A UY33722A UY33722A UY 33722 A UY33722 A UY 33722A UY 0001033722 A UY0001033722 A UY 0001033722A UY 33722 A UY33722 A UY 33722A UY 33722 A UY33722 A UY 33722A
Authority
UY
Uruguay
Prior art keywords
compounds
mglur5
oxazolidinones
modulators
agonists
Prior art date
Application number
UY0001033722A
Other languages
English (en)
Inventor
Andrew P Degnan
Huang Hong
Lawrence B Snyder
Yang Fukang
Kevin W Gillman
Michael F Parker
Original Assignee
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY33722A publication Critical patent/UY33722A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Por lo general, la descripción se refiere a compuestos de la fórmula 1, incluidas sus sales, así como a composiciones y métodos para el uso de Ios compuestos. Los compuestos son ligandos, agonistas y agonistas parciales del receptor mGluR5, y pueden ser útiles para el tratamiento de varios trastornos del sistema nervioso central.
UY0001033722A 2010-11-11 2011-11-11 Oxazolidinonas como moduladores de mglur5 UY33722A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41254110P 2010-11-11 2010-11-11

Publications (1)

Publication Number Publication Date
UY33722A true UY33722A (es) 2012-05-31

Family

ID=44999936

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033722A UY33722A (es) 2010-11-11 2011-11-11 Oxazolidinonas como moduladores de mglur5

Country Status (6)

Country Link
US (2) US8691821B2 (es)
EP (1) EP2638022B1 (es)
AR (1) AR083861A1 (es)
TW (1) TW201300369A (es)
UY (1) UY33722A (es)
WO (1) WO2012064603A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159738B (zh) * 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用
US9790203B2 (en) * 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
BR112015014579A2 (pt) 2012-12-19 2017-07-11 Basf Se compostos da fórmula i, uso de um composto da fórmula i, método para combater fungos nocivos e sementes.
US9688669B2 (en) * 2013-10-07 2017-06-27 Bristol-Myers Squibb Company Oxazolidinones as modulators of mGluR5
ES2786673T3 (es) 2015-06-03 2020-10-13 Hoffmann La Roche Derivados de etinilo
JP2025509988A (ja) * 2022-03-22 2025-04-11 アリックス セラピューティクス インコーポレイテッド Ｍｇｌｕｒ５調節化合物、組成物、及び使用方法
WO2025080252A1 (en) * 2023-10-13 2025-04-17 Allyx Therapeutics, Inc. Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
WO2025188734A1 (en) * 2024-03-06 2025-09-12 Allyx Therapeutics, Inc. Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529123A1 (en) 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
ES2332184T3 (es) 2004-03-22 2010-01-28 ELI LILLY & COMPANY Derivados de piridilo y su uso como antagonistas del receptor mglu5.
JP2011510083A (ja) * 2008-01-24 2011-03-31 メルク・シャープ・エンド・ドーム・コーポレイション ３，５−二置換−１，３−オキサゾリジン−２−オン誘導体
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US9688669B2 (en) * 2013-10-07 2017-06-27 Bristol-Myers Squibb Company Oxazolidinones as modulators of mGluR5

Also Published As

Publication number Publication date
US8691821B2 (en) 2014-04-08
USRE49735E1 (en) 2023-11-28
US20120283264A1 (en) 2012-11-08
WO2012064603A1 (en) 2012-05-18
TW201300369A (zh) 2013-01-01
EP2638022B1 (en) 2014-12-24
EP2638022A1 (en) 2013-09-18
AR083861A1 (es) 2013-03-27

Similar Documents

Publication Publication Date Title
UY33722A (es) Oxazolidinonas como moduladores de mglur5
CO6300941A2 (es) Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
ECSP16000724A (es) Carboxamidas de anillo de 4 miembros empleadas como nematicidas
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
ECSP11011098A (es) Nuevas pirazol-4-n-alcoxicarboxamidas cómo microbicidas.
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
ECSP11011206A (es) Nuevos herbicidas.
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
UY34649A (es) Compuestos heterobicíclicos
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
CU20100159A7 (es) Compuestos
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
DOP2011000217A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
GT201500159A (es) Derivados de imidazopiridazina como moduladores del receptor gabaa
ECSP11011244A (es) Nuevos herbicidas.
ECSP11011218A (es) Herbicidas derivados de ciclopentanodiona.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
PE20150966A1 (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
UY35947A (es) Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen
ECSP11011217A (es) Microbiocidas nuevos.